Chromocell Therapeutics (CHRO) Insider Trading & Ownership $0.63 0.00 (-0.16%) (As of 03:43 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Chromocell Therapeutics (NYSE:CHRO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.40%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$17,210.00Number OfInsiders Selling(Last 12 Months)0 Get CHRO Insider Trade Alerts Want to know when executives and insiders are buying or selling Chromocell Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CHRO Insider Buying and Selling by Quarter Ad Paradigm PressTrump’s EPIC Stock Market RallyPutting HUGE gain chances in the hands of hardworking, patriotic Americans like YOU. In fact, according to Jim, getting in now could turn $10,000 into as much as $265,000 by Inauguration Day.Play this epic Trump rally for every dollar of profit possible. Chromocell Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/12/2024Knuettel Francis IICEOBuy1,700$0.97$1,649.00 9/12/2024Richard MalamutDirectorBuy10,400$0.94$9,776.00 9/10/2024Knuettel Francis IICEOBuy6,500$0.89$5,785.00 (Data available from 1/1/2013 forward) CHRO Insider Trading Activity - Frequently Asked Questions Who is on Chromocell Therapeutics's Insider Roster? The list of insiders at Chromocell Therapeutics includes Knuettel Francis II, and Richard Malamut. Learn more on insiders at CHRO. What percentage of Chromocell Therapeutics stock is owned by insiders? 16.40% of Chromocell Therapeutics stock is owned by insiders. Learn more on CHRO's insider holdings. Which Chromocell Therapeutics insiders have been buying company stock? The following insiders have purchased CHRO shares in the last 24 months: Knuettel Francis II ($7,434.00), and Richard Malamut ($9,776.00). How much insider buying is happening at Chromocell Therapeutics? Insiders have purchased a total of 18,600 CHRO shares in the last 24 months for a total of $17,210.00 bought. Chromocell Therapeutics Key ExecutivesMr. Francis Knuettel II (Age 58)M.B.A., President, CEO, CFO, Treasurer, Secretary & Director Compensation: $107.5kDr. Eric Lang M.D. (Age 62)Chief Medical Officer Compensation: $264.99k More Insider Trading Tools from MarketBeat Related Companies ProPhase Labs Insider Trading Mannatech Insider Trading Avalo Therapeutics Insider Trading NRx Pharmaceuticals Insider Trading Turnstone Biologics Insider Trading Aspira Women's Health Insider Trading Talphera Insider Trading HCW Biologics Insider Trading Sensei Biotherapeutics Insider Trading Indaptus Therapeutics Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NYSE:CHRO) was last updated on 11/18/2024 by MarketBeat.com Staff From Our PartnersThis “IRS Loophole” Allows You to Do WHAT?Little-Known IRS Loophole Beats Inflation 4x Over New guide reveals how to take advantage of this federally...Gold Safe Exchange | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredTrump’s EPIC Stock Market RallyPutting HUGE gain chances in the hands of hardworking, patriotic Americans like YOU. In fact, according to ...Paradigm Press | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredA huge crack is forming in the US economyFormer Trump Advisor Warning: “An Economic Rupture Is Coming” The legendary financier Brad Thomas served on...Wide Moat Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
